Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 2, 2010, Pages 217-222

  Webster, D ^a   Long, R ^b   Shandro, C ^c   Pettipas, J ^d   Leblanc, J ^e   Davidson, R ^d   Fanning, A ^c  

^a SAINT JOHN REGIONAL HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Extra pulmonary; Fluoroquinolone; Resistance; Tuberculosis

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; DRUG EXPOSURE; DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; KIDNEY TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY DELAY; URINARY TRACT INFECTION; URINE CULTURE; XANTHOMONAS CAMPESTRIS;

ADULT; AGED; ALBERTA; ANTITUBERCULAR AGENTS; DELAYED DIAGNOSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TUBERCULOSIS, RENAL; URINARY TRACT INFECTIONS;

EID: 77049089009     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Yoon Y S, Lee H J, Yoon H I, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9: 1215-1219.
2. Enarson D A, Ashley M J, Grzybowski S, Ostapkowicz E, Dorken E. Non-respiratory tuberculosis in Canada. Am J Epidemiol 1980; 112: 341-351.
3. Fanning A. Tuberculosis: 6. Extra-pulmonary disease. CMAJ 1999; 160: 1597-1603.
4. Public Health Agency of Canada. Tuberculosis in Canada 2001. Ottawa, Canada: Health Canada, Minister of Public Works
5. and Government Services Canada, 2003. http://www.phac-aspc.gc.ca/ publicat/tbcan01/index.html Accessed November 2009.
6. Christensen W I. Genitourinary tuberculosis: review of 102 cases. Medicine 1974; 53: 377-390.
7. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory evaluation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
8. Bozeman L, Burman W, Metchock B, Welch L, Weiner M, and the Tuberculosis Trials Consortium. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386-391.
9. Eastwood J B, Corbishley C M, Grange J M. Tuberculosis and the kidney. J Amer Soc Nephro 2001; 12: 1307-1314.
10. Warren J W, Abrutyn E, Hebel J R, Johnson J R, Schaeffer A J, Stamm W E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29: 745-758.
11. Oliphant C M, Green G M. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455-464.
12. US Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR 2006; 55: 301-305.
13. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006; 55: 1176.
14. Shah N S, Wright A, Bai G, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
15. Francisco R C, Grimaldo E R, Rivera A B, Bautista T L, Co V M, Tupasi T E. Multidrug-resistant Mycobacterium tuberculosis: role of the fluoroquinolones. Proceedings. 4th Western Pacific Congress on Chemotherapy and Infectious Diseases. JAMA (Southeast Asia) 1994; 10 (Suppl): S592-S595.
16. Perlman D C, El-Sadr W M, Heifets L B, et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11: 1473-1478.
17. Riantawan P, Punnotok R, Chaisuksuwan R, Pransujarit V. Resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs in the central region of Thailand, 1996. Int J Tuberc Lung Dis 1998; 2: 616-620.
18. Casal M, Ruiz P, Herreras A, et al. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Int J Tuberc Lung Dis 2000; 4: 588-591.
19. Grimaldo E R, Tupasi T E, Rivera A B, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.
20. Hemvani N, Chitnis D S, Bhatia G C, Sharma N. Drug resistance among tubercle bacilli from pulmonary tuberculosis cases in central India. Ind J Med Sci 2001; 55: 382-392.
21. Ginsburg A S, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1452.
22. Huang T, Kunin C M, Lee S S, Chen Y, Tu H, Liu Y. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-1062.
23. Ginsburg A S, Woolwine S C, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349: 1977-1978.
24. Sullivan E A, Kreiswirth B N, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-1150.
25. Yew W W, Chan E, Chan C Y, Cheng A F. Genotypic and phenotypic resistance of Mycobacterium tuberculosis to rifamycins and fluoroquinolones. Int J Tuberc Lung Dis 2002; 6: 936-937.
26. Pitaksajjakul P, Wongwit W, Punprasit W, et al. Mutations in the gyrA and gyrB genes of the fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005; 36 (Suppl 4): S228-S237.
27. Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
28. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-442.